A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Beata HolkovaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; Correspondence[email protected]

Victor YazbeckMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA;

Maciej KmieciakMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Prithviraj BoseMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Shuo MaDivision of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA;

Amy KimballMarlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA;

Mary Beth TombesMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Ellen ShraderMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Wen WanDepartment of Statistics, Virginia Commonwealth University, Richmond, VA, USA;

Caryn Weir-WigginsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Amanda SinghMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Kevin T. HoganMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Sarah ConineMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Heidi SankalaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

John D. RobertsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Thomas C. SheaDepartment of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA;

Steven GrantMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; ;The Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA

show all

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplemental Figure 3

Supplemental Figure 2

Supplemental Figure 1

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Supplemental Figure 3

Supplemental Figure 2

Supplemental Figure 1

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date